Company

BRL MedicineCAR-T

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

The CD19‑targeted genetically modified allogeneic chimeric antigen receptor T‑cell (CAR‑T) injection of Shanghai BRL Medicine, Inc. has been included in the Center for Drug Evaluation (CDE) of China's National Medical…

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics
AIIambic Therapeutics

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Hemony PharmaceuticalInsud Pharma

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Overseas Pharmaceuticals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Adamerck PharmlabsAspen Pharmacare

Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent

Show More